



<b>Title</b>	<b>Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein</b>
<b>Author(s)</b>	<b>Yam, JWP; Jin, DY; So, CW; Chan, LC</b>
<b>Citation</b>	<b>Blood, 2004, v. 103 n. 4, p. 1445-1453</b>
<b>Issued Date</b>	<b>2004</b>
<b>URL</b>	<b><a href="http://hdl.handle.net/10722/48499">http://hdl.handle.net/10722/48499</a></b>
<b>Rights</b>	<b>Creative Commons: Attribution 3.0 Hong Kong License</b>

Left running head  
YAM et al

Right running head  
EBP, A NOVEL EEN BINDING PARTNER

Scientific section designation  
NEOPLASIA

IDENTIFICATION AND CHARACTERIZATION OF EBP, A NOVEL EEN BINDING  
PROTEIN THAT INHIBITS RAS SIGNALING AND IS RECRUITED INTO THE  
NUCLEUS BY THE MLL-EEN FUSION PROTEIN

Judy Wai Ping Yam, Dong-Yan Jin, Chi Wai So and Li Chong Chan

Department of Pathology and Department of Biochemistry, The University of Hong  
Kong, Hong Kong

## **Abstract**

The chimeric MLL-EEN fusion protein is created as a result of chromosomal translocation t(11;19)(q23;p13). EEN, an SH3 domain containing protein in the endophilin family, has been implicated in endocytosis, although little is known about its role in leukemogenesis mediated by the MLL-EEN fusion protein. In this study, we have identified and characterized EBP, a novel EEN binding protein that interacts with the SH3 domain of EEN through a proline-rich motif PPERP. EBP is a ubiquitous protein which is normally expressed in the cytoplasm but is recruited to the nucleus by MLL-EEN with a punctate localization pattern characteristic of the MLL chimeric proteins. EBP interacts simultaneously with EEN and Sos, a guanine-nucleotide exchange factor for Ras. Coexpression of EBP with EEN leads to suppression of Ras-induced cellular transformation and Ras-mediated activation of Elk-1. Taken together, our findings suggest a new mechanism for MLL-EEN-mediated leukaemogenesis in which MLL-EEN interferes with the Ras-suppressing activities of EBP through direct interaction.

Supported by grants from the Research Grants Council of the Hong Kong Special  
Administrative Region, China (Project No.: HKU7252/99M)

**Reprints:** Li Chong Chan, Department of Pathology, University Pathology Bldg, Queen  
Mary Hospital, Pokfulam, Hong Kong; e-mail: chanlc@pathology.hku.hk; phone: (852) 2855  
3160; fax: (852) 28177565

Word counts: Abstract (157 words)  
Text (4293 words)

## Introduction

Chromosomal translocations that disrupt the human homolog of the *Drosophila* trithorax (TRX) gene, MLL (mixed lineage leukemia) gene at 11q23 are frequently found in human leukemias<sup>1-3</sup>. TRX is a transcriptional activator required to maintain expression of homeotic genes during *Drosophila* embryonic development<sup>4,5</sup>. Knockout studies in mice have shown that MLL, like TRX in *Drosophila*, has a similar function in mammals with MLL heterozygous mice showing abnormal skeletal and haemopoietic development.<sup>6,7</sup> MLL encodes for a protein of 3968 amino acids with structurally complex domains. In the N terminus there are three AT hook motifs and a cysteine-rich region (CxxC motif), which is homologous to mammalian DNA methyltransferase and is responsible for DNA binding<sup>8</sup>. Regions of conservation between MLL and TRX are located in the internal plant homeodomain zinc fingers and the C terminal SET domain. Both domains are thought to function in protein-protein interaction and chromatin modification<sup>9,10</sup>.

Translocations of the MLL result in formation of chimeric proteins in which the N terminus of MLL is fused in-frame to the C terminus of fusion partners. There are at least 35 MLL fusion partners identified to date – though diverse in structure and function, they can be classified into families or groups. A group of nuclear fusion partners, including AF4, AF9, AF10, ENL, ELL, AF17, AFX1, AF6q21, CBP and P300, has been implicated in various aspects of transcriptional regulation. The remaining group of cytoplasmic fusion partners, including AF6, AF1p, Abi-1, EEN and FBP17, possesses structural domains responsible for protein-protein interaction<sup>11</sup>. While direct fusion with transcriptional effector domains resulting in aberrant transcriptional activation activities may represent a common oncogenic mechanism for certain MLL-nuclear fusion proteins<sup>12-18</sup>, the leukemogenic mechanisms mediated by MLL-cytoplasmic fusion proteins are still largely unknown.<sup>19-21</sup>

EEN, an SH3 domain containing gene of the endophilin family localized on chromosome 19p13, is fused to MLL as a result of t(11;19) chromosomal translocation in a case of infant acute myeloid leukemia<sup>22</sup>. EEN and its two related family members, EEN-B1 and EEN-B2, also known as endophilins II, I and III respectively, shared the SH3 domains that are closely related to the SH3 domain of the adaptor protein Grb2<sup>23,24,27</sup>. All three members have been reported to be binding partners of endocytic proteins, synaptojanin, dynamin and amphiphysins, which are implicated in the trafficking of synaptic vesicles in the presynaptic nerve terminal<sup>24-28</sup> and with the G-protein-coupled  $\beta$ 1-adrenergic receptor<sup>29</sup>. Unlike EEN-B1 and EEN-B2 which show restricted tissue expression mainly in the brain, EEN is ubiquitously expressed<sup>30</sup>. Little is known on the function of EEN in haemopoietic cells and the role played by EEN in MLL-EEN mediated leukaemogenesis.

In this study, we describe the identification of a cytoplasmic protein designated EBP for EEN binding protein that specifically interacts with EEN in the cytoplasm. We show that expression of MLL-EEN results in relocation of EBP from the cytoplasm into the nucleus to produce a distinct punctate pattern typical of MLL fusion proteins<sup>31,32</sup>. Our results also show that EBP possesses inhibitory effect on Ras signaling and cellular transformation induced by Ras, a property of probable biological significance and relevance in the context of MLL-EEN mediated leukaemogenesis.

## Materials and Methods

### Plasmid constructions

Various expression constructs using pAS2-1, pGADGH, pGEX1, pFLAG.CMV2 and pCS2+MT were prepared by standard molecular biology techniques and polymerase chain reaction (PCR) amplification of the described fragments. Gal4 DNA-binding (BD) vector, pAS2-1 carrying EEN with the following amino acids were made: EEN 1-368 (FL), 1-266 (NCC), 131-368 (CCSH3), 131-266 (CC) and 303-368 (SH3), EENB1 1-352 (FL) and EENB2 1-347 (FL). Gal4-BD vectors of EBP fragments 1-767 (FL) and SH3 domains (A, B, C and D) were also constructed. Gal4 activation domain (AD) vector, pGADGH carrying EBP with the following amino acids was constructed: EBP 1-767, 76-767, 94-767, 94-357, 532-767, 272-666, 272-533, 272-358, 272-342, 348-419 and  $\Delta$ 343-347 (272-533 with internal 343-347 deletion). Fragment of Sos2-C (amino acids 974-1262) was cloned into Gal4-AD. Plasmids for bacterial expression of glutathione S-transferase (GST) fusion protein were made using pGEX1: EEN 303-368 (SH3 domain), EBP 272-358 and EBP 348-419. Eukaryotic expression vector, pCS2+MT of Myc-tagged proteins were prepared as follows: EBP 1-767, 76-767, 1-358 and 532-767, and Sos2-C (amino acids 974-1262). FLAG-tagged expression vector, pFLAG-CMV-2 (Sigma) carrying EEN, EEN deletion mutants, EEN $\Delta$ SH3, EEN with nuclear localization signal (NLS), NLSEEN and NLSEEN $\Delta$ SH3 and MLL-EEN were constructed.

### Yeast two-hybrid library screening and binding assay

Library screening was performed by sequential transformation the yeast strain Y190 was first transformed with the bait, EEN1-368pAS2-1 plasmid carrying full-length EEN fused to Gal4-BD, and subsequently with the HeLa cell cDNA library constructed in the Gal4-AD plasmid, pGADGH by large-scale lithium acetate transformation protocol. The transformation mixture was spread on SD/-Trp/-Leu/-His plates, and isolated positive clones carrying potential EEN interaction proteins were assayed for  $\beta$ -galactosidase activity on filters. The library plasmids were recovered from the positive colonies and were sequenced. To test the interacting potential between two known proteins, yeast strain SFY562 were co-transformed with Gal4-BD and Gal4-AD constructs carrying the potential interacting proteins. Transformation mixtures were spread on plates with SD/-Trp/-Leu for selection of cotransformants and qualitative colony-lift filter assay was performed. For the quantitative interaction assay, the cotransformants were lysed and the  $\beta$ -galactosidase activity was quantified using the substrate o-nitrophenyl  $\beta$ -D-galactopyranoside (ONPG).

### Tissue expression study by polymerase chain reaction

The expression of EBP on a panel of human multiple tissue cDNA (Clontech) was examined by PCR. In each reaction, 0.2  $\mu$ g of human cDNA was amplified with 10 pmol of each EBP gene specific primers, EBP348F (5'-CCTCCCCCAAAGCTTTCT-3') and EBP419R (5'-AAGTACATCCCCACGCAT-3'). Normalization of tissue cDNA panel was examined by amplification of actin.

### Cell culture and transfection

HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, penicillin and streptomycin at 37°C in a humidified incubator with 5% CO<sub>2</sub> in air. Rats 6 (R6) cells<sup>33</sup> were grown in DMEM supplemented with 10% calf serum. Transfection of cells was performed by standard calcium phosphate precipitation protocol. Semiconfluent cells in 100 mm plate were transfected with 20 µg of plasmid DNA for 16 h and harvested after 48 h. For immunofluorescence staining, cells seeded on coverslips in 35 mm plate were transfected by using Fugene 6 reagent according to the manufacturer's instruction (Roche).

### **Co-immunoprecipitation**

Transfection cells were harvested, washed with ice-cold phosphate-buffered saline (PBS), and lysed on ice in NETN buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 7.4, 1× complete protease inhibitors (Roche), 1% NP-40). Lysed cells were cleared by centrifugation and supernatants were collected. Protein concentration was determined by Bradford reagent (Bio-Rad). For co-immunoprecipitation of Myc-tagged EBP and FLAG-tagged EEN, supernatants were incubated with anti-FLAG antibody (Sigma) overnight at 4°C, after which immunoprecipitates were collected with protein A-sepharose for 4 h at 4°C with constant rotation. The beads were washed five times with NET lysis buffer and boiled in sample buffer. The immunoprecipitates were subjected to 10% SDS-polyacrylamide gel electrophoresis, and the proteins were transferred to Immobilon-P membrane (Millipore). Western blots were probed by anti-Myc antibody (Santa Cruz Biotechnology) and horseradish peroxidase conjugated secondary antibody, then visualized by ECL reagents (Amersham Pharmacia Biotech).

### **GST pull-down assay**

Glutathione S-transferase (GST) fusion proteins of EEN SH3 domain and EBP proline rich region were expressed in host strain BL21(DE3). Expression of fusion proteins was induced upon the addition of isopropyl-β-D-thiogalactopyranoside to a final concentration of 0.1 mM in exponentially growing bacterial cultures at 37°C for 3 h. Bacteria were collected and lysed, and fusion proteins were purified on glutathione Sepharose beads (Amersham Pharmacia Biotech). Cell lysates prepared as described above were incubated with 5 µg of GST fusion proteins immobilized on glutathione sepharose beads for 2 h at 4°C with constant rotation. The beads were washed with NET buffer and bound proteins were eluted and prepared for Western blot analysis. Bound proteins were detected by anti-Myc antibody.

### **Immunofluorescent staining**

Cells grown on coverslips were fixed in 4% paraformaldehyde in PBS and permeabilized with 0.5% Triton X-100 in PBS for 10 min. Cells were then blocked with 5% goat serum in PBS, and incubated with primary antibodies (rabbit anti-Myc or mouse anti-FLAG antibodies) for 1 h, followed by secondary antibodies (anti-rabbit fluorescein isothiocyanate (FITC)-conjugated or anti-mouse rhodamine-conjugated) (Jackson Immunoresearch) for 45 min with extensive washing in between. Cells were counterstained with DAPI (Calbiochem) and mounted in Vectashield antifade mountant (H1000, Vector Lab). Images were captured by a fluorescence microscope equipped with CCD camera (Leica).

### **Luciferase assay**

HeLa cells in 24-well plates were transfected with different combinations of plasmids using Fugene 6 reagent. Plasmids used included pCS2+MT-EBP, pCMV2-FLAG-EEN, pUSE-RasQ61L (Upstate Biotech), pGal4-luc, pFA-Elk-1 reporter constructs (Stratagene) and an internal control pRLSV40. Cell lysates were harvested 24 hr after transfection, prepared and assayed using Dual Luciferase Reporter assay system (Promega) according to the manufacturer's instructions. Each transfection was done in triplicates. Mean values were calculated from triplicate wells and from three independent experiments.

### **Soft agar assay**

Cells were suspended at  $1 \times 10^4$ /60 mm plate with 2 ml of 0.4% Bacto-agar in DMEM containing 20% fetal calf serum and overlaid above a layer of 5 ml of 1% agar in the same medium in triplicate plates. At day 14, colonies were stained with the vital stain 2-(p-iodopenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride hydrate for 48 h at 37°C in a 5% CO<sub>2</sub> incubator, and the numbers and sizes were scored.

## Results

### Identification and tissue expression of EBP

To search for potential binding partners of EEN, we performed yeast two-hybrid screening of a HeLa cell cDNA library using the full-length EEN as bait. Two positive clones, #30 and #46 had identical nucleotide sequence. These two clones were identical to reported sequence DKFZp434D0215 (GI: 27477709) which encodes a hypothetical protein of 767 amino acids (Figure 1A). Sequence alignment between our library-screened clones and the reported sequence revealed that our clones are partial clones with an incomplete N terminal. We obtained the N terminal fragment by PCR using HeLa cell cDNA as template. The full length cDNA for the novel interacting partner of EEN named as EBP (EEN binding protein) was obtained. Structural analysis of EBP amino acid sequence revealed that it contained a proline rich region (PRR) from amino acids 320 to 350 followed by four SH3 domains in the C terminus (Figure 1A, 1B). To determine tissue distribution of EBP, the expression of EBP was studied by PCR analysis on various human tissue cDNAs. An expected amplified product of 213-bp was obtained and sequenced. Similar to EEN that is ubiquitously expressed<sup>30</sup>, EBP was detected in all adult and fetal tissues being tested (Figure 1C). The concomitant tissue distribution of EBP and EEN suggests that the two proteins are possibly to be binding partners in various tissues.

### EEN SH3 domain is the EBP-interacting domain

Full-length EEN was used as bait in the yeast two-hybrid library screening. Structurally, EEN comprises a central coiled coil domain and a SH3 domain in the C terminus, which are domains responsible for protein-protein interaction<sup>34</sup>. In order to map the minimal EBP-interacting domain of EEN, various EEN deletion fragments fused with the Gal4-BD in the pAS2-1 plasmid were co-transformed with clone #30, one of the positive clones of EBP into the SFY562 yeast reporter strain (Figure 2A). Among the constructs tested, only the full-length EEN and mutants carrying the SH3 domain showed positive interaction with EBP (Figure 2B, 2C). The SH3 domain of EEN was shown to be binding domain of EBP. The EBP-EEN interaction was further confirmed by an in vitro GST pull down assay. Specific binding with Myc-tagged EBP was observed with the GST-EEN fusion protein containing the SH3 domain of EEN (GST-SH3) protein but not with the control GST protein (Figure 2D).

### Differential interaction of EBP with EEN family members

As the sequences of the SH3 domains are highly conserved among the EEN family members, we therefore examined whether the other two members, EEN-B1 and EEN-B2 could also interact with EBP. The colony lift filter assay showed that EBP positively interacted with EEN and EEN-B2, but interaction with EEN-B1 was barely detected (Figure 3A). The quantitative  $\beta$ -galactosidase assay further demonstrated that EBP had the strongest interaction with EEN (Figure 3B). Although EEN family members are known to interact with common proteins, for instance, synaptojanin, dynamin via the highly conserved SH3 domain<sup>30</sup>, the discrepancies in SH3 domains sequence identity between EEN, B1 and B2 might confer the binding specificity to each of the members (Figure 3C).

## **Proline rich binding motif of EBP is required for interacting with EEN**

Using yeast two-hybrid cotransformation assay, we showed that full-length EBP was able to interact with EEN (Figure 4A). To map the interacting region of EBP for EEN, constructs carrying various deletion mutants of EBP fused with the Gal4-AD were constructed and co-transformed with EEN Gal4-BD plasmid into yeast strain SFY526. The minimal binding region of EEN was mapped to amino acids 342 to 358 of EBP. Within this minimal region, a putative EEN-binding motif, PPERP (amino acids 343-347) is located which matches the consensus proline rich binding motif, PPXRP previously reported to interact with the SH3 domain of endophilins/EEN<sup>34</sup>. Interaction with EEN via the proline rich motif in residues 343 to 347 was further confirmed by an internal deletion construct  $\Delta$ 343-347 which showed no interaction with EEN. Specific interaction between EEN with the proline rich binding motif was confirmed by an *in vitro* GST pull down assay (Figure 4B). In this experiment, Myc-tagged EEN expressed in HeLa cell lysate was pulled down by fragment of EBP (amino acids 272 to 358) containing the putative EEN-binding motif expressed as a GST fusion protein immobilized on glutathione beads. No interaction was observed between EEN and another proline rich sequence, PPRPKP of EBP resides in amino acids 348 to 419 revealed that interaction between EEN and EBP was specifically mediated through the proline rich binding motif, PPERP in amino acids 343-347. To explore the interaction of EEN and EBP *in vivo*, Myc-tagged full length EBP (1-767) and partial EBP (76-767) were transiently transfected with either FLAG-tagged EEN or SH3 domain deletion mutant EEN $\Delta$ SH3 into HeLa cells. Myc-tagged EBP was co-immunoprecipitated with intact FLAG-tagged EEN. Deletion of the SH3 domain of EEN abrogated its interaction with EBP (Figure 4C).

## **EBP co-localizes and interacts with EEN *in vivo***

To determine the subcellular localization of EBP, Myc-tagged EBP was transiently transfected into HeLa cells. The expression of the Myc-tagged proteins in transfected cells was visualized by anti-Myc antibody, followed by FITC-conjugated antibody. EBP was observed to be evenly distributed in the cytoplasm (Figure 5A). The N terminal of EBP from amino acids 1 to 358 including the proline rich region also displayed similar cytoplasmic localization when transiently expressed in the HeLa cells (Figure 5B). However, the C terminal of EBP from amino acids 532 to 767 consists of the last three SH3 domains showed localization both in the cytoplasm with a uniform pattern and also in the nucleus with a punctate distribution (Figure 5C). This observation could be the result of the loss of structural domain, located within the N terminal domain that is responsible for retaining EBP in the cytoplasm.

To determine whether EBP and EEN share similar subcellular localization, Myc-tagged EBP was expressed either alone or together with FLAG-tagged EEN in HeLa cells. Simultaneous ectopic expression of EBP and EEN in transfected cells displayed uniform cytoplasmic localization (Figure 5D). To test whether EBP and EEN could interact with each other *in vivo*, a nuclear localization signal (NLS) was added to EEN that would redirect EEN from the cytoplasm into the nucleus. HeLa cells transfected with Myc-tagged EBP and FLAG-tagged NLSEEN resulted in nuclear localization of both proteins (Figure 5E). In addition, NLSEEN with a deletion in SH3 domain, the EBP binding domain, was unable to bring EBP into the nucleus (Figure 5F). This observation supports direct physical interaction between EBP and EEN *in vivo* as well as a role of the SH3 domain of EEN in interacting and modulating the subcellular localization of EBP.



## **MLL-EEN fusion protein delocalizes EBP into the nucleus**

The native nuclear localization of the MLL-EEN fusion gene prompts us to study the effect of coexpression of EBP and MLL-EEN in cells. In HeLa cells expressing exogenously introduced EBP and MLL-EEN, EBP is localized in both cytoplasm and nucleus (Figure 5G). MLL-EEN and EBP both exhibited a punctate localization in the nucleus, a pattern also reported for other MLL fusion proteins<sup>32</sup>. Our study shows that MLL-EEN could only partially relocate EBP into the nucleus while NLSEEN could more efficiently relocate EBP into the nucleus. The difference in the ability of MLL-EEN and EEN in relocating EBP may be due to the significant protein size difference between the two proteins. We postulate that the relatively large protein size of MLL-EEN (1715 amino acids) as compared with EEN (368 amino acids) might prevent access of the EBP-binding domain in EEN to EBP. Under this circumstance, MLL-EEN would not be able to interact with all EBP proteins present inside the cells and relocate them all from the cytoplasm into the nucleus. Our results demonstrate that EEN specifically interacts with EBP, and its subcellular localization as a MLL-EEN fusion protein can directly affect the subcellular localization of EBP.

## **EBP interacts with EEN and Sos2 simultaneously**

Structural comparison of EBP with known proteins revealed that EBP is similar to intersectin, an endocytic protein with multiple SH3 domains in the C terminal<sup>35,36</sup>. Moreover, Son of sevenless (Sos), a guanine-nucleotide exchange factor of Ras was identified as a SH3 domain-binding partner of intersectin<sup>37,38</sup>. To study the potential interaction between EBP and Sos, we performed yeast two-hybrid cotransformation assay to test the interaction between deletion mutants of EBP fused to Gal4-BD and the C terminal of Sos1 and Sos2 (Sos1-C and Sos2-C) fused to Gal4-AD. EBP was found to interact with Sos2 but not with Sos1 (data not shown). Our results showed that two pairs of the consecutive SH3 domains (SH3 B-C and SH3 C-D) of EBP were sufficient to interact with Sos2 (Figure 6A). The specific interactions between EBP SH3 domains and Sos2 were also demonstrated by the *in vitro* GST pull-down assay. In this assay, the first two SH3 domains of EBP (SH3 A-B) were unable to pull down Sos2, while SH3 B-C and SH3 C-D could efficiently bind Sos2 (Figure 6B). By using quantitative liquid culture assay of the yeast cotransformants, the last two SH3 domains (SH3 C-D) had the highest binding affinity to Sos2 (Figure 6C).

Our results show that EBP has distinct binding sites for EEN and Sos2, and EEN and Sos2 do not interact with each other (data not shown). To address the question whether EBP is able to interact with EEN and Sos simultaneously and form a stable trimeric protein complex, we performed a co-immunoprecipitation reaction followed by a GST pull-down assay. Myc-tagged EBP and Sos2-C were transfected into HeLa cells and incubated with GST-EENSH3 fusion protein immobilized on glutathione sepharose beads. Both Myc-tagged proteins could be differentiated by their significant protein size difference. EBP-Myc protein could be pulled down by GST-EENSH3, and Sos2-C-Myc could only be detected when EBP-Myc was cotransfected (Figure 6D).

## **Expression of EBP and EEN inhibits Ras transformation potential and Ras-mediated activation of Elk-1**

Association of EBP with Sos2, a guanine exchange factor of Ras prompts us to investigate the effect of EBP and EEN on Ras-induced cellular transformation. Stable transfectants of R6 cells expressing dominant active mutant, RasQ61L with or without EBP and/or EEN were

examined for anchorage-independent growth on soft agar. Normal R6 cells remained as single cells while R6 cells induced by RasQ61L formed large colonies (size range: 0.05-0.68 mm) (Figure 7A, 7B). Cotransfection of RasQ61L with EBP and EEN showed up to 40% and 70% reductions in the number and size of colonies (size range: 0.05-0.27 mm). The expressions of EEN and EBP in stable transfectants were detected by Western blot analysis (Figure 7C).

EBP displays high structural similarity with the multiple SH3 domains in the C terminal of intersectin, which reported to interact with Sos and activate Elk-1 activation<sup>39,40</sup>, we therefore investigate the effect of EBP on the downstream signaling of Ras by performing luciferase assay using Gal4-Elk-1 trans-reporter. Expression of RasQ61L, a constitutively active mutant enhanced the activation of Elk-1 trans-reporter by 6-fold (Figure 7D). When EBP and EEN were cotransfected with RasQ61L, activation of Elk-1 transcription factor by RasQ61L was reduced by 45%, and the effect of inhibition by EBP and EEN was more efficient than expression of either EBP or EEN alone. However, this inhibitory effect was lost when NLSEEN and EBP were transfected. Since NLSEEN interacts and relocates EBP into the nucleus (Figure 5E), therefore our reporter assays suggest that the inhibitory effect of EEN and EBP on activation of Elk-1 requires the cytoplasmic localization of both EEN and EBP. The inhibition effect of EBP and EEN on the basal activity and Ras-mediated activation of Elk-1 occurred in a dose-dependent manner (Figure 7F). Taken together, our results show that EBP and EEN cooperatively inhibit Ras signaling, and also suppress cellular transformation induced by Ras.

## Discussion

EEN was originally identified as a MLL fusion partner in acute myeloid leukaemia<sup>22</sup> and preliminary studies based on retroviral transduction of mice haemopoietic stem cells indicates EEN is necessary for MLL mediated leukemogenesis (So et al., unpublished data). To investigate the role of EEN in the pathogenesis of leukaemia, we have identified and characterized a ubiquitously expressed protein, EBP, as a novel binding partner of EEN. Structurally, EBP comprises an N terminal region, a central proline rich region, followed by four SH3 domains in the C terminal. Fine mapping of EBP reveals a proline rich binding motif, PPERP (residues 343-347) which interacts with the SH3 domain of EEN and is consistent with the consensus endophilin binding sequence, PPXRP<sup>34</sup>. Specific and direct interaction between EBP and EEN was further confirmed by the in vitro GST pull-down assay and in vivo co-immunoprecipitation studies (Figure 4). In spite of the high sequence homology of the SH3 domains among the EEN family members, the preferential interaction between EEN and EBP (Figure 3) further strengthens the notion that EBP is a bona fide interacting partner for EEN and each EEN member may have related but distinct functional roles in cell signaling.

Structural and functional analysis shows that EBP shares some similarity to intersectin, an adaptor protein with multiple SH3 domains that interacts with Son of sevenless (Sos), a guanine-nucleotide exchange factor and activator of Ras<sup>38</sup>. Analogous to intersectin, EBP recruits Sos2 via its SH3 domains to form a stable trimeric complex with EEN mediated by its consensus endophilin binding sequence. Intersectin has been shown to regulate the Ras/MAP kinase pathway and activate Elk-1 transcription factor resulting in oncogenic transformation of rodent cells<sup>38-40</sup>. Over expression of a dominant negative mutant with SH3 domains of intersectin repressed the activation of Ras and Elk-1<sup>39</sup>, and failed to induce transformation<sup>40</sup>. In contrast to intersectin, the expression of EBP not only suppressed the transcriptional activation of Elk-1 but also Ras-induced oncogenic transformation (Figure 7). Moreover, coexpression of EEN significantly enhanced the inhibitory effects on Ras-mediated transactivation and transformation (Figure 7), suggesting that the EEN-EBP-Sos trimeric complex likely contributes to the observed repressive effects. Taken together, these results indicate that EBP acts as an adaptor module in the EEN-EBP-Sos2 complex and that it cooperates with EEN to inhibit the Ras-stimulating activity of Sos2. In this context, EBP and EEN could be viewed to possess tumor suppressor properties in the negative feedback control of Ras-mediated signaling and cellular transformation.

To investigate the potential effect of MLL-EEN fusion on this trimeric complex, we also demonstrated that MLL-EEN oncoprotein displayed punctate nuclear localization pattern (Figure 8), which accords with several studies showing that the N terminus of MLL is responsible for targeting fusion protein into the nucleus where it exerts its oncogenic potential<sup>31</sup>. Interestingly, EBP is relocated from cytoplasm into the nucleus, and displayed similar punctate nuclear localization pattern by MLL-EEN oncoprotein. These results strongly indicate that MLL-EEN fusion not only has a dosage but also a dominant negative effect on the native EEN and EBP proteins which inhibit Sos2 and Ras signaling. We speculate that this subversion of the tumor-suppressing activities of EEN and EBP could contribute to constitutive Ras activation and cellular transformation.

There is growing evidence that interaction of the Ras signaling pathway may be a common biological phenomenon for several MLL fusion partners. Notably, both Sos1 and

Sos2 were also identified as the binding partners for Abl interactor 1 (Abi-1), another MLL cytoplasmic fusion partner that shares structural similarity with EEN has an SH3 domain at the C terminus<sup>41</sup>. E3b1/Abi-1 was originally isolated as the binding protein of Eps8, an SH3 domain containing protein that plays a role in mitogenic signaling<sup>42,43</sup>. Abi-1 and Sos-1 form a trimeric complex with Eps8 that mediates transduction of signals from Ras to Rac<sup>44</sup>, and is required for the inhibition of growth factor- and v-Abl-mediated activation of Erk<sup>45</sup>. MLL fusion proteins including the AF4 family and AF6 are also involved in Ras signaling<sup>46-48</sup> and N-ras and K-ras mutation have been reported for leukemia patients with MLL translocation other than MLL-EEN or MLL-Abi-1<sup>49,50</sup>.

The pathological significance of the Ras-mediated pathways in MLL leukemogenesis is further strengthened by the identification of EEN SH3 domain as a minimal transformation domain required for MLL-EEN mediated myeloid transformation (So et al., unpublished data). Although gain of function on MLL-dependent pathways is likely the most critical primary or initiating event among the multiple events for MLL fusion mediated leukemogenesis, we present evidence to suggest that deregulation of Ras-signaling pathways by either MLL fusion proteins or cooperative secondary mutations might represent one of the key secondary events required for expression of the full leukemic phenotype.

## **Acknowledgements**

We thank Cary So and Michael Cheung for technical assistance. We also acknowledge Professor Stephen P. Goff for generously providing the Sos1 and Sos2 plasmids and Dr. Wendy W. L. Hsiao for providing the R6 cell line.

## References

1. Ziemer-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. *Proc Natl Acad Sci U S A*. 1991;88:10735-10739.
2. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of *Drosophila* trithorax by 11q23 chromosomal translocations in acute leukemias. *Cell*. 1992;71:691-700.
3. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. *Nat Genet*. 1992;2:113-118.
4. Breen TR, Harte PJ. Trithorax regulates multiple homeotic genes in the bithorax and Antennapedia complexes and exerts different tissue-specific, parasegment-specific and promoter-specific effects on each. *Development*. 1993;17:119-134.
5. Van Lohuizen M. The trithorax-group and polycomb-group chromatin modifiers: implications for disease. *Curr Opin Genet Dev*. 1999;9:355-361.
6. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. *Proc Natl Acad Sci U S A*. 1998;95:10632-10636.
7. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. *Nature*. 1995;378:505-508.
8. Cross SH, Meehan RR, Nan X, Bird A. A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. *Nat Genet*. 1997;16:256-259.
9. Aasland R, Gibson, TJ, Stewart AF. The PHD finger: implications for chromatin-mediated transcriptional regulation. *Trends Biochem Sci*. 1995;20:56-59.
10. Rozenblatt-Rosen O, Rozovskaia T, Burakov D, et al. The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. *Proc Natl Acad Sci U S A*. 1998;95:4152-4157.
11. DiMartino JF, Cleary ML. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. *Br J Haematol*. 1999;106:614-626.
12. DiMartino JF, Miller T, Ayton PM, et al. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. *Blood*. 2000;96:3887-3893.
13. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. *Blood*. 2002;99:3780-3785.

14. Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. *Proc Natl Acad Sci U S A*. 2000;97:10984-10989.
15. Luo RT, Lavau C, Du C, et al. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. *Mol Cell Biol*. 2001;21:5678-5687.
16. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. *Mol Cell Biol*. 1998;18:122-129.
17. So CW, Cleary ML. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. *Mol Cell Biol*. 2002;22:6542-6552.
18. So CW, Cleary ML. Common mechanism for oncogenic activation of MLL by forkheadfamily proteins. *Blood*. 2003;101:633-639.
19. Corral J, Lavenir I, Impey L, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. *Cell*. 1996;85:853-861.
20. Dobson CL, Warren AJ, Pannell R, et al. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. *EMBO J*. 1999;18:3564-3574.
21. Lavau C, Szilvassy SJ, Slany R, Cleary ML. immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. *EMBO J*. 1997;16:4226-4237.
22. So CW, Caldas C, Liu MM, et al. EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia. *Proc Natl Acad Sci U S A*. 1997;94:2563-2568.
23. Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. *Cell*. 1992;70:431-442.
24. Ringstad N, Nemoto Y, De Camilli P. The SH3p4/Sh3p8/SH3p13 protein family: binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3 domain. *Proc Natl Acad Sci U S A*. 1997;94:8569-8574.
25. Micheva KD, Kay BK, McPherson PS. Synaptojanin forms two separate complexes in the nerve terminal. Interactions with endophilin and amphiphysin. *J Biol Chem*. 1997;272:27239-27245.

26. Micheva KD, Ramjaun AR, Kay BK, McPherson PS. SH3 domain-dependent interactions of endophilin with amphiphysin. *FEBS Lett.* 1997;414:308-312.
27. So CW, So CKC, Cheung N, Chew SL, Sham MH, Chan LC. The interaction between EEN and Abi-1, two MLL fusion partners, and synaptojanin and dynamin: implications for leukaemogenesis. *Leukemia.* 2000;14:594-601.
28. Nemoto Y, Wenk MR, Watanabe M, et al. Functional characterization of a mammalian Sac1 and mutants exhibiting substrate-specific defects in phosphoinositide phosphatase activity. *J Biol Chem.* 2000;276:41133-41142.
29. Tang Y, Hu LA, Miller WE, et al. Identification of the endophilins (SH3p4/p8/p13) as novel binding partners for the beta1-adrenergic receptor. *Proc Natl Acad Sci U S A.* 1999;96:12559-12564.
30. So CW, Sham MH, Chew SL, et al. Expression and protein-binding studies of the EEN gene family, new interacting partners for dynamin, synaptojanin and huntingtin proteins. *Biochem J.* 2000;348:447-458.
31. Caslini C, Alarcòn AS, Hess JL, Yanaka R, Murti KG, Biondi A. The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds. *Leukemia.* 2000;14:1898-1908.
32. Simone F, Polak PE, Kaberlein JJ, Luo RT, Levitan DA, Thirman MJ. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. *Blood.* 2001;98:201-209.
33. Freeman AE, Black PH, Vanderpool EA, Henry PH, Austin JB, Huebner RJ. Transformation of primary rat embryo cells by adenovirus type 2. *Proc Natl Acad Sci U S A.* 1967;58:1205-1212.
34. Ringstad N, Nemoto Y, De Camilli P. Differential expression of endophilin 1 and 2 dimers at central nervous system synapses. *J Biol Chem.* 2001;276:40424-40430.
35. Guipponi M, Scott HS, Chen H, Schebesta A, Rossier C, Antonarakis SE. Two isoforms of a human intersectin (ITSN) protein are produced by brain-specific alternative splicing in a stop codon. *Genomics.* 1998;53:369-376.
36. Pucharcos C, Estivill X, Luna S de la. Intersectin 2, a new multimodular protein involved in clathrin-mediated endocytosis. *FEBS Lett.* 2000;478:43-51.
37. Yamabhai M, Hoffman NG, Hardison, NL, et al. Intersectin, a novel adaptor protein with two Eps15 homology and five Src homology 3 domains. *J Biol Chem.* 1998;273:31401-31407.
38. Tong XK, Hussain NK, de Heuvel E, et al. The endocytic protein intersectin is a major binding partner for the Ras exchange factor mSos1 in rat brain. *EMBO J.* 2000;19:1263-1271.



39. Tong XK, Hussain NK, Adams A, O'Bryan JP, McPherson PS. Intersectin can regulate the Ras/MAP kinase pathway independent of its role in endocytosis. *J Biol Chem.* 2000;19:29894-29899.
40. Adams A, Thorn JM, Yamabbai M, Kay BK, O'Bryan JP. Intersectin, an adaptor protein involved in clathrin-mediated endocytosis, activates mitogenic signaling pathways. *J Biol Chem.* 2000;275:27414-37420.
41. Taki T, Shibuya N, Taniwaki M, et al. ABI-1, a human homolog to mouse Abl-interactor 1, fuses the MLL gene in acute myeloid leukemia with t(10;11)(p11.2;q23). *Blood.* 1998;92:1125-1130.
42. Biesova Z, Piccoli C, Wong WT. Isolation and characterization of e3B1, an eps8 binding protein that regulates cell growth. *Oncogene.* 1997;14:233-241.
43. Fazioli F, Minichiello L, Matoska V, et al. Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals. Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals. *EMBO J.* 1993;12:3799-3808.
44. Scita G, Nordstrom J, Carbone R, et al. EPS8 and E3B1 transduce signals from Ras to Rac. *Nature.* 1999;401:290-293.
45. Fan PD, Goff SP. Abl interactor 1 binds to sos and inhibits epidermal growth factor- and v-Abl-induced activation of extracellular signal-regulated kinases. *Mol Cell Biol.* 2000;20:7591-7601.
46. Wittwer F, van der Straten A, Keleman K, Dickson BJ, Hafen E. Lilliputian: an AF4/FMR2-related protein that controls cell identity and cell growth. *Development.* 2001;128:791-800.
47. Linnemann T, Geyer M, Jaitner BK, et al. Thermodynamic and kinetic characterization of the interaction between the Ras binding domain of AF6 and members of the Ras subfamily. *J Biol Chem.* 1999;274:13556-13562.
48. Quilliam LA, Castro AF, Rogers-Graham KS, Martin CB, Der CJ, Bi C. M-Ras/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6. *J Biol Chem.* 1999;274:23850-23857.
49. Mahgoub N, Parker RI, Hosler MR, et al. RAS mutations in pediatric leukemias with MLL gene rearrangements. *Genes Chrom Cancer.* 1998;21:270-275.
50. Naoe T, Kubo K, Kiyoi H, et al. Involvement of the MLL/ALL-1 gene associated with multiple point mutations of the N-ras gene in acute myeloid leukemia with t(11;17)(q23;q25) *Blood.* 1993;82:2260-2261.

## Figure legends

**Figure 1. Structure and tissue expression of EBP.** (A) Schematic representation of EBP. EBP encodes a protein of 767 amino acids and comprises a central proline rich region (PRR) followed by four SH3 domains. The SH3 domains are indicated by black boxes and the PRR is shown as hatched box. Clone #30 and #46 were obtained from yeast two-hybrid library screening. Reported sequence DKFZp434D0215 (GI: 27477709) that shows nucleotide sequence identity with EBP is aligned for comparison. (B) Deduced amino acid sequence of EBP. The PRR within amino acids 320-350 is bold. Putative EEN-binding motif, PPERP in amino acids 343-347 is marked by asterisks. Four SH3 domains located in amino acids 473-529, 552-606, 639-696 and 708-765 are underlined. (C) Tissue expression of EBP. Analysis of EBP expression by PCR in multiple human adult (1-8) and fetal (9-16) tissue cDNAs. Arrowheads indicate specific PCR products amplified. PCR of actin is included as control. Heart (1, 9); brain (2, 10); placenta (3); lung (4, 11); liver (5, 12); skeletal muscle (6, 13); kidney (7, 14); pancreas (8); spleen (15); thymus (16); water (17); EBP plasmid DNA (18); 100-bp ladder marker (M).

**Figure 2. EEN SH3 domain mediates interaction with EBP.** (A) Schematic representation of deletion mutants of EEN used in the yeast two-hybrid transformation assay. The hatched box indicates the central coiled coil domain (CC) and the black box denotes the SH3 domain. FL and N represent the full-length and N terminus of EEN respectively. (B) Yeast two-hybrid transformation assay. Deletion mutants of EEN fused to Gal4-BD in pAS2-1 plasmid were co-transformed with clone #30 fused to Gal4-AD in pGADGH plasmid into yeast strain SFY526. Colony lift filter assay was then performed on the co-transformants. Positive interaction is indicated by + and no interaction is represented by -. (C) Colony lift filter assay. Positive X-gal staining was observed in co-transformants expressing FL/clone #30, and SH3/clone #30, but not in negative controls, FL/pGADGH and pAS2-1/clone#30. (D) GST pull-down assay. HeLa cells total cell lysate expressing Myc-tagged EBP was incubated with either GST or GST-SH3 (SH3 domain of EEN) immobilized on glutathione beads, and the bound proteins were detected with anti-Myc antibody. TCL, 10% of total cell lysate used in the assay.

**Figure 3. Differential interaction of EBP with EEN family members.** (A) Yeast transformation assay of EBP with EEN family members. Clone #30 in Gal4-AD plasmid was co-transformed with each EEN family member, EEN, B1 and B2 cloned in Gal4-BD plasmid into yeast strain SFY526. Positive interaction accessed by colony lift filter assay is indicated by +. (B) Quantitative liquid culture assay. Lysates of cotransformants were quantified with ONPG substrate. Each data point represents the average  $\pm$  SD of three independent experiments. (C) Amino acids alignment of the SH3 domains of EEN family members. Identical residues are indicated by dashes and consensus residues among family are marked by asterisks.

**Figure 4. Proline rich motif of EBP is responsible for binding with EEN SH3 domain.** (A) Yeast transformation assay of EBP with EEN. Schematic diagram of deletion constructs of EBP is shown. The PRR and SH3 domains are represented by hatched and black boxes respectively. The arrowheads locate the putative proline rich binding motifs, PPERP within amino acids 343-347, and PPRPKP within amino acids 400-405. Deletion mutants of EBP cloned in Gal4-AD plasmid were each co-transformed with EEN Gal4-BD plasmid into yeast strain SFY526. Positive interaction accessed by colony lift filter assay is indicated by +. (B)

GST pull down assay. Extract of HeLa cells expressing Myc-tagged EEN was incubated with GST, GST-EBP272-358 or GST-EBP348-419 immobilized on glutathione beads. Binding protein was detected with anti-Myc antibody. (C) Interaction of EBP with EEN in vivo. Lysates of HeLa cells transfected with Myc-tagged EBP1-767 or EBP76-767 and/or FLAG-tagged EEN or SH3 domain deletion mutant, EEN $\Delta$ SH3 FLAG were subjected to immunoprecipitation (IP) with anti-FLAG antibody followed by anti-Myc immunoblotting (WB). TCL was immunoblotted with anti-Myc antibody. The positions of immunoblotted proteins are indicated by arrowheads. The nonspecific immunoglobulin heavy chain is marked by an arrow.

**Figure 5. Expression of EEN and MLL-EEN relocate EBP.** (A, B, C) Subcellular localization of Myc-tagged EBP 1-767, EBP 1-358, and EBP 532-767. (D) EEN and EBP co-localize in the cytoplasm. (E) NLSEEN interacts and recruits EBP from the cytoplasm into the nucleus. (F) NLSEEN $\Delta$ SH3 mutant unable to relocate EBP into the nucleus. (G) MLL-EEN partially relocates EBP into the nucleus. HeLa cells were transiently transfected with Myc-tagged EBP with FLAG-tagged EEN or MLL-EEN. EBP and EEN/MLL-EEN were visualized by anti-Myc and anti-FLAG antibodies, followed by FITC-conjugated anti-rabbit and rhodamine-conjugated anti-mouse antibodies respectively. Nucleus in each case was visualized by Dapi staining. Overlaid of Dapi-, FITC- and rhodamine-stained images are shown in the last column.

**Figure 6. EBP interacts with EEN and Sos2 simultaneously.** (A) Yeast transformation assay of EBP with Sos2. Schematic diagram of deletion constructs of EBP is presented. Deletion mutants of EBP cloned in Gal4-BD plasmid were each co-transformed with Sos2 Gal4 DNA-AD into yeast strain SFY526. Positive interaction accessed by colony lift filter assay is indicated by +. (B) GST pull down assay. Extract of HeLa cells expressing Myc-tagged Sos2-C was incubated with GST or GST-EBP SH3 domains (SH3 A-B, B-C or C-D) immobilized on glutathione beads. Binding protein was detected with anti-Myc antibody. (C) Quantitative assay for EBP-EEN interaction. Transformants of Gal4-BD and Gal4-AD fusion pairs were assayed using ONPG substrate. Relative  $\beta$ -galactosidase activity was expressed as arbitrary units. (D) Simultaneous interaction of EBP with Sos2 and EEN in vivo. Lysates of HeLa cells transfected with Myc-tagged EBP and/or Sos2-C were incubated with GST-EENSH3 fusion protein immobilized on glutathione beads. Bound proteins were detected by anti-Myc antibody.

**Figure 7. EBP and EEN inhibit the transformation potential of Ras and Ras-mediated activation of Elk-1.** (A, B) Colony formation in soft agar assay. R6 cells ( $1 \times 10^4$ ) stably transfected with empty vector, RasQ61L, RasQ61L+EBP-Myc, RasQ61L+EEN-FLAG and RasQ61L+EBP-Myc+EEN-FLAG were suspended in 0.4% agar and overlaid in 1% bottom agar. Representative colonies were photographed (A) and number of colonies was scored after 12 days (C). (B) Expression of exogenous EBP-Myc and EEN-FLAG in stably transfected R6 cells was confirmed by Western blot analysis. (D) EBP and EEN inhibit Ras-mediated activation of Elk-1. HeLa cells were transiently transfected with combinations of expression vectors shown. (E) NLSEEN and EBP lack inhibitory effect on Ras-mediated activation of Elk-1. (F) Dosage dependent inhibition of EBP and EEN on the Elk-1 transactivation by Ras. For all the reporter assays, total amount of expression vectors was equalized with the empty vector, and transfection efficiency was normalized by a positive control, pRL-SV40. At 48 h after transfection, luciferase activity was determined and

normalized with the Renilla luciferase activity. Data shown represents means and error bar indicates standard deviation of three independent experiments.